Suppr超能文献

血液透析和持续性非卧床腹膜透析对慢性肾衰竭患者体内离子转运异常的影响。

Effects of haemodialysis and continuous ambulatory peritoneal dialysis on abnormalities of ion transport in vivo in patients with chronic renal failure.

作者信息

Brearley C J, Aronson J K, Boon N A, Raine A E

机构信息

MRC Unit, Radcliffe Infirmary, Oxford, U.K.

出版信息

Clin Sci (Lond). 1993 Dec;85(6):725-31. doi: 10.1042/cs0850725.

Abstract
  1. We have studied Na+/K+ pump activity in vivo in three groups of subjects: patients with chronic renal failure not receiving maintenance dialysis, patients being treated by either haemodialysis or continuous ambulatory peritoneal dialysis, and matched control subjects. 2. To do this we have measured the changes in plasma and intraerythrocytic rubidium concentrations after an oral load of rubidium chloride, having previously shown that changes in the disposition of rubidium measured in this way reflect changes in the activity of the Na+/K+ pump in vivo. 3. Erythrocyte rubidium uptake was significantly reduced both in ten patients with chronic renal failure not receiving maintenance dialysis and in 12 patients being treated by haemodialysis, when compared with 31 healthy control subjects. In contrast, erythrocyte rubidium uptake was not altered in 13 patients treated by continuous ambulatory peritoneal dialysis. There was also a significantly reduced rate constant for erythrocyte rubidium uptake in patients with undialysed chronic renal failure (0.66 h-1) and in those treated by haemodialysis (0.78 h-1), whereas in patients treated by continuous ambulatory peritoneal dialysis the rate constant for erythrocyte rubidium uptake was not significantly different from control values (1.36 h-1 and 1.41 h-1, respectively). 4. These findings are consistent with a reversal of the inhibition of erythrocyte Na+/K+ pump activity in vivo found in chronic renal failure by continuous ambulatory peritoneal dialysis, but not by haemodialysis. This difference may be due to the failure of haemodialysis to clear a circulating inhibitor of Na+, K(+)-ATPase or to the rapid re-accumulation of such an inhibitor after haemodialysis.(ABSTRACT TRUNCATED AT 250 WORDS)
摘要
  1. 我们研究了三组受试者体内的钠钾泵活性:未接受维持性透析的慢性肾衰竭患者、接受血液透析或持续性非卧床腹膜透析治疗的患者以及相匹配的对照受试者。2. 为此,我们在口服氯化铷负荷后测量了血浆和红细胞内铷浓度的变化,此前已表明以这种方式测量的铷处置变化反映了体内钠钾泵活性的变化。3. 与31名健康对照受试者相比,10名未接受维持性透析的慢性肾衰竭患者和12名接受血液透析治疗的患者的红细胞铷摄取均显著降低。相比之下,13名接受持续性非卧床腹膜透析治疗的患者的红细胞铷摄取未改变。未透析的慢性肾衰竭患者(0.66 h⁻¹)和接受血液透析治疗的患者(0.78 h⁻¹)的红细胞铷摄取速率常数也显著降低,而接受持续性非卧床腹膜透析治疗的患者的红细胞铷摄取速率常数与对照值(分别为1.36 h⁻¹和1.41 h⁻¹)无显著差异。4. 这些发现与持续性非卧床腹膜透析而非血液透析可逆转慢性肾衰竭患者体内红细胞钠钾泵活性抑制的情况一致。这种差异可能是由于血液透析未能清除循环中的钠钾ATP酶抑制剂,或由于血液透析后此类抑制剂迅速重新蓄积。(摘要截短为250字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验